Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with lower risk of major adverse cardiovascular events and death from any cause, but there was no clear effect on nonfatal myocardial infarction and researchers noted an adverse effect for nonfatal stroke.
The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from adults with type 2 diabetes, according to an accompanying editorial.
Incretin-based drugs not associated with greater heart failure hospitalization risk than other drug combos in retrospective study
Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.
New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5.
The presence of an insulin pump should not preclude an appropriate and medically indicated CT scan, the FDA said.